ALNY vs. DVA: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ALNY and DVA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ALNY’s market capitalization of 43.28 billion USD is substantially larger than DVA’s 10.76 billion USD, indicating a significant difference in their market valuations.
DVA carries a higher beta at 1.11, indicating it’s more sensitive to market moves, while ALNY (beta: 0.21) exhibits greater stability.
| Symbol | ALNY | DVA |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | DaVita Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Care Facilities |
| CEO | Yvonne L. Greenstreet | Javier J. Rodriguez |
| Price | 331.91 USD | 142.56 USD |
| Market Cap | 43.28 billion USD | 10.76 billion USD |
| Beta | 0.21 | 1.11 |
| Exchange | NASDAQ | NYSE |
| IPO Date | June 1, 2004 | October 31, 1995 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ALNY and DVA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ALNY
-509.33%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
ALNY has a negative Return on Equity of -509.33%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
DVA
393.58%
Medical - Care Facilities Industry
- Max
- 37.16%
- Q3
- 13.80%
- Median
- 6.51%
- Q1
- -11.55%
- Min
- -43.55%
DVA’s Return on Equity of 393.58% is exceptionally high, placing it well beyond the typical range for the Medical - Care Facilities industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Return on Invested Capital
ALNY
-2.79%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ALNY has a negative Return on Invested Capital of -2.79%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
DVA
11.25%
Medical - Care Facilities Industry
- Max
- 20.36%
- Q3
- 9.05%
- Median
- 5.41%
- Q1
- -1.08%
- Min
- -9.00%
In the upper quartile for the Medical - Care Facilities industry, DVA’s Return on Invested Capital of 11.25% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
ALNY
-11.49%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
ALNY has a negative Net Profit Margin of -11.49%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
DVA
6.63%
Medical - Care Facilities Industry
- Max
- 12.40%
- Q3
- 6.23%
- Median
- 3.17%
- Q1
- -3.80%
- Min
- -13.43%
A Net Profit Margin of 6.63% places DVA in the upper quartile for the Medical - Care Facilities industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
ALNY
-4.91%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ALNY has a negative Operating Profit Margin of -4.91%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
DVA
15.77%
Medical - Care Facilities Industry
- Max
- 17.86%
- Q3
- 10.40%
- Median
- 6.40%
- Q1
- 0.40%
- Min
- -10.86%
An Operating Profit Margin of 15.77% places DVA in the upper quartile for the Medical - Care Facilities industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ALNY | DVA |
|---|---|---|
| Return on Equity (TTM) | -509.33% | 393.58% |
| Return on Assets (TTM) | -6.40% | 5.02% |
| Return on Invested Capital (TTM) | -2.79% | 11.25% |
| Net Profit Margin (TTM) | -11.49% | 6.63% |
| Operating Profit Margin (TTM) | -4.91% | 15.77% |
| Gross Profit Margin (TTM) | 86.01% | 32.46% |
Financial Strength
Current Ratio
ALNY
3.04
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ALNY’s Current Ratio of 3.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
DVA
1.25
Medical - Care Facilities Industry
- Max
- 2.67
- Q3
- 1.76
- Median
- 1.35
- Q1
- 1.12
- Min
- 0.57
DVA’s Current Ratio of 1.25 aligns with the median group of the Medical - Care Facilities industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
ALNY
11.28
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
With a Debt-to-Equity Ratio of 11.28, ALNY operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
DVA
-46.13
Medical - Care Facilities Industry
- Max
- 2.55
- Q3
- 1.40
- Median
- 0.76
- Q1
- 0.26
- Min
- 0.01
DVA has a Debt-to-Equity Ratio of -46.13, which indicates negative shareholder equity where liabilities exceed assets. This is a critical sign of financial distress.
Interest Coverage Ratio
ALNY
-0.79
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ALNY has a negative Interest Coverage Ratio of -0.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
DVA
4.04
Medical - Care Facilities Industry
- Max
- 16.29
- Q3
- 6.85
- Median
- 2.93
- Q1
- 0.35
- Min
- -7.11
DVA’s Interest Coverage Ratio of 4.04 is positioned comfortably within the norm for the Medical - Care Facilities industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ALNY | DVA |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 1.25 |
| Quick Ratio (TTM) | 2.98 | 1.20 |
| Debt-to-Equity Ratio (TTM) | 11.28 | -46.13 |
| Debt-to-Asset Ratio (TTM) | 0.31 | 0.72 |
| Net Debt-to-EBITDA Ratio (TTM) | -1.85 | 4.46 |
| Interest Coverage Ratio (TTM) | -0.79 | 4.04 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ALNY and DVA. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
DVA
0.00%
Medical - Care Facilities Industry
- Max
- 2.79%
- Q3
- 0.08%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
DVA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
ALNY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALNY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
DVA
0.00%
Medical - Care Facilities Industry
- Max
- 56.48%
- Q3
- 4.48%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
DVA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ALNY | DVA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio
ALNY
-159.59
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ALNY has a negative P/E Ratio of -159.59. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
DVA
13.16
Medical - Care Facilities Industry
- Max
- 40.40
- Q3
- 28.24
- Median
- 24.89
- Q1
- 13.53
- Min
- 8.53
In the lower quartile for the Medical - Care Facilities industry, DVA’s P/E Ratio of 13.16 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Forward P/E to Growth Ratio
ALNY
-43.29
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
ALNY has a negative Forward PEG Ratio of -43.29. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
DVA
0.94
Medical - Care Facilities Industry
- Max
- 4.23
- Q3
- 3.06
- Median
- 1.16
- Q1
- 0.77
- Min
- 0.04
DVA’s Forward PEG Ratio of 0.94 is within the middle range of its peers in the Medical - Care Facilities industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
ALNY
18.43
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ALNY’s P/S Ratio of 18.43 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
DVA
0.83
Medical - Care Facilities Industry
- Max
- 2.38
- Q3
- 1.50
- Median
- 0.79
- Q1
- 0.49
- Min
- 0.04
DVA’s P/S Ratio of 0.83 aligns with the market consensus for the Medical - Care Facilities industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
ALNY
372.86
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
DVA
-42.36
Medical - Care Facilities Industry
- Max
- 7.73
- Q3
- 4.07
- Median
- 2.16
- Q1
- 1.44
- Min
- 0.66
DVA has a negative P/B Ratio of -42.36, indicating its liabilities exceed its assets and result in negative shareholder equity. This is a critical warning sign of financial distress.
Valuation at a Glance
| Symbol | ALNY | DVA |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -159.59 | 13.16 |
| Forward PEG Ratio (TTM) | -43.29 | 0.94 |
| Price-to-Sales Ratio (P/S, TTM) | 18.43 | 0.83 |
| Price-to-Book Ratio (P/B, TTM) | 372.86 | -42.36 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -574.08 | 6.12 |
| EV-to-EBITDA (TTM) | -285.32 | 8.50 |
| EV-to-Sales (TTM) | 18.55 | 1.75 |